Abstracts Archive - Page 1444 of 2425 - ACR Meeting Abstracts

Abstract Number: 391 • 2016 ACR/ARHP Annual Meeting
A Single Centre Experience from India on the Safety and Efficacy of Cipla Etanercept and Intas Etanercept and Its Comparison with Reference Etanercept(Enbrel) in Children with JIA
Abhay Shivpuri¹, Sumidha Mittal², Manjari Agarwal³ and Sujata Sawhney⁴, ¹Division of Pediatric Rheumatology,Institute of Child Health, Post Doctoral Fellow, New Delhi, India, ²Post Doctoral Fellow, New Delhi, India, ³Institute of Child Health, Attending Consultant, New Delhi, India, ⁴Paediatric rheumatology, Senior Consultant, New Delhi, India
Background/Purpose: Cost is a major impediment for use of biologic response modifiers (BRMs). Biosimilars/Intended copies, priced at almost half the reference molecule might be the…
Abstract Number: 392 • 2016 ACR/ARHP Annual Meeting
Safety and Clinical Response of Weekly Adalimumab in the Treatment of Juvenile Idiopathic Arthritis, Pediatric Chronic Uveitis and Other Childhood Rheumatic Diseases
Colleen K. Correll¹, Danielle R. Bullock¹, Rachel Cafferty¹ and Richard K Vehe², ¹Pediatrics, University of Minnesota, Minneapolis, MN, ²University of Minnesota Masonic Children’s Hospital, Minneapolis, MN
Background/Purpose: Every other week adalimumab is used to treat juvenile idiopathic arthritis (JIA) and other pediatric rheumatic diseases. It is common for pediatric rheumatologists to…
Abstract Number: 393 • 2016 ACR/ARHP Annual Meeting
Association of Sex, Race and Ethnicity on Disease Outcomes in Juvenile Idiopathic Arthritis Patients
Vivek Joseph¹, Tracy R. Andrews², Esi Morgan³, Ronald Laxer⁴, cagri Toruner⁵, Tzielan Lee^6,7, Beth S. Gottlieb⁸, C. April Bingham⁹, Sheetal S. Vora¹⁰, Jon M. Burnham¹¹, Judyann C. Olson¹², Murray H. Passo¹³, Michelle Batthish¹⁴, Meredith Riebschleger¹⁵ and Jennifer E. Weiss¹⁶, ¹Internal Medicine, Rutgers New Jersey Medical School, Bloomfield, NJ, ²Biostatistics, David & Alice Jurist Institute, Hackensack University Medical Center, hackensack, NJ, ³Pediatric Rheumatology, Cincinnati Children's Hospital, Cincinnati, OH, ⁴Div of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁵Rheumatology, Nationwide Children's Hospital, Columbus, OH, ⁶Dept of Pediatric Rheumatology, Stanford Univ School of Med, Palo Alto, CA, ⁷Pediatric Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ⁸Pediatric Rheumatology, The Steven and Alexandra Cohen Children's Medical Center of New York, The Hofstra North Shore-LIJ School of Medicine, New Hyde Park, NY, ⁹Penn State Health Children's Hospital, Hershey, PA, ¹⁰Pediatric Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ¹¹Pediatric Rheumatology, Children's Hospital Philadelphia, Philadelphia, PA, ¹²Ped/MACC Fund Research Ctr, Medical College of Wisconsin, Milwaukee, WI, ¹³Division of Rheumatology PTD, Medical University of South Carolina, Charleston, SC, ¹⁴Division of Pediatric Rheumatology, McMaster Children's Hospital, Hamilton, ON, Canada, ¹⁵Pediatric Rheumatology, University of Michigan, CS Mott Children's Hospiatl, Ann Arbor, MI, ¹⁶Hackensack Univ Med Ctr, Hackensack, NJ
Background/Purpose: JIA patients are predominantly non-Hispanic white and studies have shown that race and ethnicity may be associated with worse disease. This study assesses the…
Abstract Number: 394 • 2016 ACR/ARHP Annual Meeting
Effect of BMI on Symptoms and Outcomes in Juvenile Idiopathic Arthritis Patients
Jennifer E. Weiss¹, Tracy Andrews², Esi Morgan³, Ronald Laxer⁴, Cagri Yildirim-Toruner⁵, C. April Bingham⁶, Beth Gottlieb⁷, Tzielan Lee⁸, Sheetal S. Vora⁹, Jon M. Burnham¹⁰, Judyann C. Olson¹¹, Murray Passo¹², Michelle Batthish¹³ and Meredith Riebschleger¹⁴, ¹Hackensack Univ Med Ctr, Hackensack, NJ, ²Biostatistics, David & Alice Jurist Institute, Hackensack University Medical Center, hackensack, NJ, ³Pediatric Rheumatology, Cincinnati Children's Hospital, Cincinnati, OH, ⁴Div of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁵Rheumatology, Nationwide Children's Hospital, Columbus, OH, ⁶Penn State Health Children's Hospital, Hershey, PA, ⁷Pediatric Rheumatology PTD, Cohen Children's Medical Center of New York, Lake Success, NY, ⁸Dept of Pediatric Rheumatology, Stanford Univ School of Med, Palo Alto, CA, ⁹Pediatric Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ¹⁰Pediatric Rheumatology, Children's Hospital Philadelphia, Philadelphia, PA, ¹¹Ped/MACC Fund Research Ctr, Medical College of Wisconsin, Milwaukee, WI, ¹²Pediatric Rheumatology, Medical University of South Carolina, Charleston, SC, ¹³Division of Pediatric Rheumatology, McMaster Children's Hospital, Hamilton, ON, Canada, ¹⁴Pediatric Rheumatology, University of Michigan, CS Mott Children's Hospiatl, Ann Arbor, MI
Background/Purpose: Children with JIA are at risk for cardiovascular disease and obesity compounds this risk. There is limited data on the prevalence of elevated BMI…
Abstract Number: 395 • 2016 ACR/ARHP Annual Meeting
The Influence of Early Achievement of “Clinically Inactive Disease” or “Minimal Disease Activity” on Long-Term Disability Outcomes in JIA
Stephanie J.W.Shoop^1,2, Suzanne M.M. Verstappen³, Janet E. McDonagh⁴, Wendy Thomson^5,6, Kimme L. Hyrich^3,7 and CAPS, ¹Central Manchester University Hospitals NHS Foundation Trust and University of Manchester Partnership, NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, ²The University of Manchester, Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁴Faculty of Medical and Human Sciences, Centre for MSK Research, Manchester, United Kingdom, ⁵Arthritis Research UK Centre for Genetics and Genomics,The University of Manchester, Manchester, United Kingdom, ⁶NIHR Manchester Musculoskeletal Biomedical Research Unit, Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ⁷Arthritis Research UK, Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Different definitions of clinically inactive disease (CID) for JIA have recently been shown to identify different groups of children. It is unclear whether long-term…
Abstract Number: 396 • 2016 ACR/ARHP Annual Meeting
Performance of Disease Activity Measures in Juvenile Spondyloarthritis in a Placebo Controlled Trial with Infliximab
Sofia Ramiro¹, Julio Casasola², Désirée van der Heijde³, RBM Landewé⁴ and Rubén Burgos-Vargas⁵, ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Hospital General de Mexico, Mexico, Mexico, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁵Rheumatology, Hospital General de Mexico, Mexico city, Mexico
Background/Purpose: Several outcome measures in trials with juvenile-onset spondyloarthritis (Jo-SpA) have been borrowed from trials in juvenile idiopathic arthritis and from adult spondyloarthritis, but a…
Abstract Number: 397 • 2016 ACR/ARHP Annual Meeting
Comorbidities Associated with Pediatric Psoriatic Arthritis
Cynthia Manos¹, Rui Xiao², Alexis Ogdie³, Timothy Brandon⁴ and Pamela F. Weiss^5,6, ¹Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA, ⁴Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, ⁵Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁶Division of Rheumatology, Center for Pediatric Clincial Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: In adults, psoriatic arthritis (PsA) is associated with an increased prevalence of obesity, hypertension, and diabetes. It is not yet known if pediatric patients…
Abstract Number: 398 • 2016 ACR/ARHP Annual Meeting
Predictors of Clinical Remission with Etanercept in Pediatric Patients with Extended Oligoarticular, Enthesitis-Related Arthritis and Psoriatic Arthritis: Findings from the Clipper Study
Nicolino Ruperto¹, Alessandro Consolaro², Gerd Horneff¹, Rubén Burgos-Vargas¹, Tamas Constantin¹, Ivan Foeldvari¹, Jelena Vojinovic¹, Joke Dehoorne¹, Violeta Vladislava Panaviene¹, Gordana Susic¹, Valda Stanevicha¹, Katarzyna Kobusinska¹, Zbigniew Zuber³, Richard Mouy¹, Ingrida Rumba-Rozenfelde¹, Pavla Dolezalová¹, Chantal Job-deslandre⁴, Nico M Wulffraat¹, Ronald Pedersen⁵, Jack F Bukowski⁶, Tina Hinnershitz⁷, Bonnie Vlahos⁸ and Alberto Martini⁹, ¹Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ²Istituto Giannina Gaslini, Genoa, Italy, ³St Louis Children’s Hospital ODS Rheumatology and Neurology, Krakow, Poland, ⁴Pediatria II, Reumatologia, PRINTO, Istituto Giannina Gaslini, Genoa, Italy, ⁵Department of Biostatistics, Pfizer, Collegeville, PA, ⁶Clinical Affairs, Pfizer, Collegeville, PA, ⁷Specialty Care MDG, Pfizer, Collegeville, PA, ⁸GIPB - Clinical Sciences, Pfizer, Collegeville, PA, ⁹PRINTO-IRCCS, Genoa, Italy
Background/Purpose: Etanercept (ETN) is approved in the EU for the treatment of children with juvenile idiopathic arthritis (JIA) categories of polyarticular, extended oligoarticular (eoJIA), enthesitis-related…
Abstract Number: 399 • 2016 ACR/ARHP Annual Meeting
Enthesitis in Juvenile Idiopathic Arthritis (JIA)
Dax G. Rumsey¹, Jaime Guzman², Alan Rosenberg³, Adam Huber⁴, Rosie Scuccimarri⁵, Dean Eurich⁶ and Research in Arthritis in Canadian Children Emphasizing Outcomes (ReACCh-Out) Investigators, ¹Paediatrics, University of Alberta, Edmonton, AB, Canada, ²Rheumatology, BC Children's Hospital, Vancouver, BC, Canada, ³Pediatrics, Pediatrics, Saskatoon, SK, Canada, ⁴IWK Health Centre, Halifax, NS, Canada, ⁵Division of Pediatric Rheumatology, Montreal Children's Hospital / McGill University Health Centre, Montreal, QC, Canada, ⁶University of Alberta, Edmonton, AB, Canada
Enthesitis in Juvenile Idiopathic Arthritis (JIA) Background/Purpose: The characteristics of enthesitis, a feature in some children with juvenile idiopathic arthritis (JIA), t has not been…
Abstract Number: 400 • 2016 ACR/ARHP Annual Meeting
Foot Involvement in Enthesitis-Related Arthritis Subtype of Juvenile Idiopathic Arthritis: Clinical, Radiological and Functional Assessment
Sanat Phatak¹, Namita Mohindra², Abhishek Zanwar¹ and Amita Aggarwal¹, ¹Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Radiodiagnosis, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Though foot involvement is common in juvenile idiopathic arthritis (JIA), it is often neglected by patients and physicians alike. The involvement could occur due…
Abstract Number: 401 • 2016 ACR/ARHP Annual Meeting
Humoral Immune Response after a Booster Dose with Tdap in Children and Adolescents with Juvenile Idiopathic Arthritis on Anti-TNF and in Healthy Controls
Aline Nicacio¹, Octavio Peracchi², Juliana Yamada³, Fernanda Spina³, Brunna Alvarenga³, Maria Isabel Pinto³ and Maria Teresa Terreri⁴, ¹Pediatric Rheumatology Unit, Department of Pediatrics, Federal University of Sao Paulo, Sao Paulo, Brazil, Sao Paulo, Brazil, ²Pediatric Rheumatology, Federal University of Sao Paulo, Department of Pediatrics, Sao Paulo, Brazil, Sao Paulo, Brazil, ³Federal University of Sao Paulo, Department of Pediatrics, Sao Paulo, Brazil, Sao Paulo, Brazil, ⁴Pediatric Rheumatology Unit, Federal University of São Paulo, São Paulo, Brazil
Background/Purpose: Pertussis cases have increased worldwide and knowledge on immune response after adult Tdap vaccine is scarce. This study evaluated the humoral immune response profile…
Abstract Number: 402 • 2016 ACR/ARHP Annual Meeting
The Risk of Hospitalized Infection Associated with Initiation of Abatacept Versus TNF Inhibitors in Juvenile Idiopathic Arthritis
Timothy Beukelman¹, Fenglong Xie², John Baddley³, Lang Chen², Melissa Mannion⁴, Kenneth G. Saag⁵, Jie Zhang⁶ and Jeffrey R. Curtis⁵, ¹Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Pediatrics, University of Alabama at Birmingham, Birmingham, AL, ⁵Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Epidemilogy, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The comparative risk of infection with newer biologic agents, such as abatacept (ABA), in the treatment of juvenile idiopathic arthritis (JIA) has not been…
Abstract Number: 403 • 2016 ACR/ARHP Annual Meeting
High Rate of Serious Infection in Juvenile Idiopathic Arthritis Under Biologic Therapy in a Real Life Setting
Juliana Brunelli¹, Ana Renata Schmidt¹, Adriana M E Sallum², Cláudia Goldenstein-Schainberg³, Eloisa Bonfa⁴, Clovis A Silva⁵ and Nadia E Aikawa⁶, ¹Pediatric Rheumatology, University of São Paulo, São Paulo, Brazil, ²Pediatric Rheumatology Unit, University of São Paulo, São Paulo, Brazil, ³Rheumatology Division, University of São Paulo, São Paulo, Brazil, ⁴Rheumatology Divison, Hospital das Clinicas, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil, ⁵Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁶Pediatric Rheumatology, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Most data about infections associated to biologic therapy in juvenile idiopathic arthritis (JIA) derive from registries designed to identify general adverse events that have…
Abstract Number: 404 • 2016 ACR/ARHP Annual Meeting
Disease Activity and Damage in Juvenile Idiopathic Arthritis: Comparison Between “Methotrexate” and “Biologic” Era
Gabriella Giancane¹, Valentina Muratore², Valentina Marzetti³, Neus Quilis⁴, Belen Serrano⁵, Alessandra Alongi⁵, Adele Civino⁶, Lorenzo Quartulli⁷, Alessandro Consolaro², Alberto Martini² and Angelo Ravelli², ¹Pediatria II, Reumatologia, PRINTO, Istituto Giannina Gaslini, Genoa, Italy, ²Istituto Giannina Gaslini, Genoa, Italy, ³IRCCS G. Gaslini, Genoa, Italy, ⁴Pediatria II Reumatologia, IRCCS G. Gaslini, Genoa, Italy, ⁵Pediatria II, IRCCS G. Gaslini, Genoa, Italy, ⁶Azienda Ospedaliera Card G Panico, Tricase, Italy, ⁷UOC Pediatria - AO "Card.G.Panico", Tricase, Italy
Background/Purpose: The introduction of biologic agents at the beginning of the 2000s has represented a major advance in the management of juvenile idiopathic arthritis (JIA).…
Abstract Number: 405 • 2016 ACR/ARHP Annual Meeting
Patterns of Medication Use in Children with Juvenile Idiopathic Arthritis: Results from the Childhood Arthritis & Rheumatology Research Alliance Registry
Sarah Ringold¹, Yukiko Kimura², Laura E. Schanberg³, Marc D. Natter⁴, Fenglong Xie⁵, Norman Ilowite⁶, Jason Jones⁷, Kelly Mieszkalski⁸, Timothy Beukelman⁹ and for the CARRA Registry Investigators, ¹Pediatrics, Seattle Children's Hospital, Seattle, WA, ²Hackensack University Medical Center, Hackensack, NJ, ³Pediatrics, Duke Medical Center, Durham, NC, ⁴Intelligent Health Labs, Children's Hospital Boston, Boston, MA, ⁵Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Division of Pediatric Rheumatology, Children's Hospital at Montefiore, Bronx, NY, ⁷Childhood Arthritis and Research Rheumatology Alliance (CARRA), Durham, NC, ⁸Childhood Arthritis and Rheumatology Research Alliance (CARRA), Durham, NC, ⁹Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry is a multicenter, prospective observational study collecting data from children with rheumatic diseases in order…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].